When Insurance Denies Your Skin Medication

What a Prior Authorization Denial Actually Means

Prior authorization is a plan requirement that a clinician document, before or at the time of prescribing, that a medication meets the insurer's coverage criteria. Medicare Advantage plans, which are run by private insurers under Medicare rules, commonly use prior authorization the same way commercial plans do — the insurer isn't necessarily saying no to the drug itself, it's saying the paperwork on file doesn't yet satisfy its rule 1Ref 1Centers for Medicare & Medicaid Services (2024).Medicare Advantage & other health plans.That Medicare Advantage plans, run by private insurers, commonly use prior authorization and network rules the way commercial plans do..

In practice, a first denial is often just a missing or incomplete form rather than a considered rejection. Calling the pharmacy or the insurer to ask exactly which criterion wasn't met — a specific diagnosis code, a documented prior treatment, a lab value — turns a vague denial into something the dermatologist's office can directly fix and resubmit.

Why Dermatology Medications Get Flagged for Step Therapy

Step therapy requires trying and documenting failure of a lower-cost option before the plan will cover a more expensive one, and dermatology has several drug classes built around exactly that kind of ladder. Systemic and biologic treatments for moderate-to-severe eczema, for instance, are recommended by dermatology guidelines specifically for patients who haven't adequately responded to topical therapy first 2Ref 2Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.That systemic and biologic eczema therapies are recommended for patients with inadequate response to topical therapy first, the clinical basis for step-therapy requirements on these drugs., and the same tiered logic applies to psoriasis, where topical corticosteroids and steroid-sparing topical agents are the first-line step before anything systemic is considered appropriate 3Ref 3American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids and steroid-sparing topical agents are the first-line step in psoriasis treatment before systemic therapy, the clinical basis for step-therapy requirements in psoriasis..

That means a denial for a biologic or other systemic drug often isn't disputing whether the condition is severe enough — it's asking for proof that the topical step was actually tried, for how long, and with what result. If that trial happened but was never logged in the chart in a way the insurer can see, the fix is documentation, not a different drug.

The "Not Medically Necessary" Denial: Medical vs. Cosmetic

Some dermatology denials aren't about step therapy at all — they're a determination that the drug is cosmetic rather than medically necessary, and plans exclude cosmetic prescriptions from coverage as a matter of policy. Hair loss treatment is the clearest example: evidence supports topical minoxidil, oral finasteride, and low-level laser therapy for androgenetic alopecia 4Ref 4Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.That minoxidil, finasteride, and low-level laser therapy are evidence-supported treatments for androgenetic alopecia, used to illustrate the gap between clinical evidence and a plan's cosmetic coverage classification., but many plans still categorize the prescription version as elective, regardless of the underlying evidence, because hair loss itself is classified as cosmetic in the plan's coverage rules.

An appeal against this kind of denial has to argue medical necessity directly — documenting a diagnosis, functional or psychological impact, and why the specific drug is the appropriate treatment — rather than simply re-submitting the same prescription and hoping for a different outcome.

Building the Appeal: What to Ask Your Dermatologist For

A letter of medical necessity is the single most useful document in a dermatology drug appeal, and a strong one names the specific diagnosis, cites what's already been tried and for how long, and references the guideline supporting the requested treatment for that severity of disease. National acne guidelines, for example, distinguish between strongly recommended options and those recommended more conditionally 5Ref 5Reynolds RV, Yeung H, Cheng CE, et al. (2024).Guidelines of care for the management of acne vulgaris.The distinction between strongly and conditionally recommended acne treatments in AAD guidance, used as the standard a letter of medical necessity can cite to support a specific requested treatment. — a dermatologist citing that a patient's case meets the criteria for a strongly recommended treatment, after documented failure of milder options, gives the insurer's reviewer a specific standard to approve against rather than a general request to reconsider.

Asking the prescribing office directly for this letter, rather than assuming the pharmacy or insurer will request it, is usually what moves a stalled prior authorization forward.

Internal Appeal vs. External Review

Most plans have two tiers: an internal appeal, reviewed by the insurer itself, and if that fails, an external review by an independent third party not affiliated with the insurer. The specific deadlines and required forms vary by plan and by state, and are listed in the denial letter itself — that letter is worth keeping, since it's also usually the document that starts the appeal clock.

An expedited or urgent appeal process typically exists for situations where waiting for the standard timeline would risk the patient's health, and it's worth asking explicitly whether a case qualifies for that faster track rather than assuming only the standard process is available.

Bridging the Gap While an Appeal Is Pending

Manufacturer patient-assistance and copay-savings programs exist for many brand-name dermatology drugs and can reduce or eliminate the out-of-pocket cost while an appeal works through the system, though eligibility usually depends on insurance status and income. The prescribing office's staff, or the drug manufacturer's own patient-support line listed on its website, is generally the fastest way to find out whether a specific medication has one and how to enroll.